Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal

Core Insights - Roche's mid-stage study ZUPREME-1 for petrelintide, an investigational obesity treatment, met its primary endpoint, indicating significant weight loss compared to placebo [2][5][8] - The drug is co-developed with Zealand Pharma, enhancing Roche's position in the growing obesity therapeutics market [2][9] - Roche's shares have increased by 27.6% over the past six months, outperforming the industry growth of 20.4% [3] Study Details - The ZUPREME-1 study involved 493 participants with a mean BMI of 37 kg/m², demonstrating statistically significant weight loss after 28 weeks [4][5] - Petrelintide achieved a mean weight loss of up to 10.7% at week 42, compared to 1.7% for placebo [5][8] - The drug showed favorable tolerability, with no vomiting cases and high maintenance dose adherence among participants [6][9] Future Development - Roche and Zealand Pharma plan to advance to Phase III development based on final data and combination studies with CT-388 [8][10] - Upcoming results from the ZUPREME-1 study will inform the Phase III strategy for petrelintide [10] - A second Phase II study, ZUPREME-2, is expected to report data in the second half of 2026, focusing on patients with obesity and type II diabetes [11] Competitive Landscape - Roche is entering a competitive obesity market dominated by Eli Lilly and Novo Nordisk, but the promising data from CT-388 represents a positive development [12][13] - Eli Lilly leads with its tirzepatide-based therapies, while Novo Nordisk has a strong position with semaglutide-based treatments [13][14] - Roche's current Zacks Rank is 3 (Hold), indicating a cautious outlook in the market [14]